Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine IM for Acute Agitation in Schizophrenia and Bipolar I
NCT05803642Phase 3Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of olanzapine in schizophrenia and bipolar I disorder (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Change from baseline on the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) at 2 hours. Status: unknown.
02
Drugs
olanzapine
03
Conditions
schizophreniabipolar I disorder
Beyond the preview
Go deeper on NCT05803642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05803642.